Remodelin has been widely used in multiple cancers, which includes melanoma [134], multiple myeloma [132], nasopharyngeal carcinoma [109], gastric cancer [46, 110], cervical cancer [135], breast cancer [106], esophageal squamous cell carcinoma [166], osteosarcoma [162] and et al. The combination of NAT10 inhibitors with other therapies—such as sorafenib [109], MDM2 inhibitors [110], CTLA-4 antibody [106, 107], and PD-1/PD-L1 antibody [49] —has shown synergistic antitumor effects (Table 3). Here, NAT10 is linked to esophageal squamous cell carcinoma.